These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

473 related items for PubMed ID: 11120976

  • 41. Increasing extended-spectrum beta-lactamase production and quinolone resistance among Gram-negative bacilli causing intra-abdominal infections in the Asia/Pacific region: data from the Smart Study 2002-2006.
    Ko WC, Hsueh PR.
    J Infect; 2009 Aug; 59(2):95-103. PubMed ID: 19564044
    [Abstract] [Full Text] [Related]

  • 42. Emerging fluoroquinolone-resistance for common clinically important gram-negative bacteria in Taiwan.
    Sheng WH, Chen YC, Wang JT, Chang SC, Luh KT, Hsieh WC.
    Diagn Microbiol Infect Dis; 2002 Jun; 43(2):141-7. PubMed ID: 12088622
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Activity of gatifloxacin tested against isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (North America, 1998-2003).
    Fedler KA, Jones RN, Sader HS, Fritsche TR.
    Diagn Microbiol Infect Dis; 2006 Jun; 55(2):157-64. PubMed ID: 16529904
    [Abstract] [Full Text] [Related]

  • 45. Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).
    Jones RN, Pfaller MA, SENTRY Antimicrobial Surveillance Program Participants Group (USA).
    Diagn Microbiol Infect Dis; 2001 Apr; 39(4):237-43. PubMed ID: 11404067
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012.
    Sader HS, Farrell DJ, Flamm RK, Jones RN.
    Int J Antimicrob Agents; 2014 Apr; 43(4):328-34. PubMed ID: 24630306
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms.
    Almer LS, Hoffrage JB, Keller EL, Flamm RK, Shortridge VD.
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2771-7. PubMed ID: 15215148
    [Abstract] [Full Text] [Related]

  • 50. In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.
    Qadri SM, Ueno Y, Burns JJ, Almodovar E, Rabea N.
    Chemotherapy; 1992 Jul; 38(2):99-106. PubMed ID: 1317282
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Resistance of Stenotrophomonas maltophilia to Fluoroquinolones: Prevalence in a University Hospital and Possible Mechanisms.
    Jia W, Wang J, Xu H, Li G.
    Int J Environ Res Public Health; 2015 May 13; 12(5):5177-95. PubMed ID: 25985315
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. In vitro activity of clinafloxacin against fluoroquinolone resistant Spanish clinical isolates.
    López-Brea M, Prieto N, Domingo D, de las Cuevas C, Sánchez I, Alarcón T.
    Int J Antimicrob Agents; 1999 Jun 13; 12(1):33-9. PubMed ID: 10389645
    [Abstract] [Full Text] [Related]

  • 55. Ceftriaxone activity against Gram-positive and Gram-negative pathogens isolated in US clinical microbiology laboratories from 1996 to 2000: results from The Surveillance Network (TSN) Database-USA.
    Karlowsky JA, Jones ME, Mayfield DC, Thornsberry C, Sahm DF.
    Int J Antimicrob Agents; 2002 May 13; 19(5):413-26. PubMed ID: 12007850
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. In vitro antimicrobial activity of gatifloxacin compared with other quinolones against clinical isolates from cancer patients.
    Rolston KV, Vaziri I, Frisbee-Hume S, Streeter H, LeBlanc B.
    Chemotherapy; 2004 Nov 13; 50(5):214-20. PubMed ID: 15523180
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.